Trial Profile
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 17 Apr 2019 Status changed from recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 12 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2019.